PERBANDINGAN RESPONS KEMOTERAPI DAN EFEK SAMPING PENGGUNAAN PLATINUM DOUBLET KOMBINASI EGFR TKI DENGAN PLATINUM DOUBLET TUNGGAL PADA PENDERITA NSCLC MUTASI GEN EGFR PROGRESSIVE DISEASE
EGFR-TKI is the first-line therapy for EGFR-mutant patients. Nevertheless, patients will have disease progression (median PFS 10 – 12 months) due to resistance. The treatment options are still limited in developing countries for such cases, thus double-platinum chemotherapy is the next option. Altho...
Saved in:
Main Author: | Edward Pandu Wiriansya |
---|---|
Format: | Theses and Dissertations NonPeerReviewed |
Language: | English English |
Published: |
2017
|
Subjects: | |
Online Access: | http://repository.unair.ac.id/66955/1/abstrak.pdf http://repository.unair.ac.id/66955/2/FIX.pdf http://repository.unair.ac.id/66955/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universitas Airlangga |
Language: | English English |
Similar Items
-
Clinical Benefit of EGFR-TKI in Management of NSCLC
by: Siprianus Ugroseno Yudho Bintoro
Published: (2017) -
Response Evaluation on Single Common and Uncommon EGFR Mutation on First-Generation EGFR-TKI Therapy in NSCLC Patients
by: Rena Arusita Maranatha, et al.
Published: (2021) -
Role of BIM deletion polymorphism and BIM expression as predictive biomarkers to maximize the benefit of EGFR-TKI treatment in EGFR-Positive NSCLC
by: Pimpin Incharoen, et al.
Published: (2020) -
Robust doublet STDP in a floating-gate synapse
by: Gopalakrishnan, Roshan, et al.
Published: (2015) -
An analysis of some tonally differentiated doublets in White Hmong (Miao)
by: Ratliff, Martha
Published: (2024)